📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Référence presse grand public
Cité 2 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 lamanchelibre.fr · 12/12/2025
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxPcy1iUHlWVE5IS3lOcng2X0tPdVg1a3B4QnQzY2pmVFFkeEdfODVvd21RZlZiekxOMG9yS3BDbUE2YmFkZHlwXzR0MlowWEpyYndNcGJmbFNfNmpLQjUweXBBN0FNS0llMVNuZE9wbl9IYlMycWVUcV9YbWRCM3FaY1ZiaC03VFAyWjA4SzFDTWVucTNIZmhiZzVQSTQtaGtBSm1Gdk1LMkFVcDNCRjAyeWlDWm1YMTFvbz
📰 Ouest-France · 08/12/2025
<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxONC1ZRTVYRl94ajVyeEZYR1Y4d3NneVpybll6aHp1OFBTbmJqQmNsR3lLdmVYM0plQWg5OURCQktfdFBMcVNCU1RsRktlekxzTG5KV01UYXlCazd5cWZKak5CSnVEeERkZEIzS0hvbGt0WVNnc2h3S3JaSlA3S0ZzV2o1WUxsbE1YZlJIU1dLYXF2bElPRDZDNXVxeTZweDBOeU1IMnY2RE5NS3h0YUVLc1o2UXRzOHgwVE
RMD open · 2023
Objectives We aimed to describe patients with autoimmune diseases (AID) developing invasive fungal disease (IFD) and identify factors associated with short-term mortality. Methods We analysed cases of IFD associated with AID from the surveillance network of invasive fungal diseases (Réseau de surveillance des infections fongiques invasives, RESSIF) registry of the French national reference centre for invasive mycoses. We studied association of AID-specific treatments with 30-day mortality. We analysed total lymphocyte and CD4-T cell counts in patients with Pneumocystis jirovecii pneumonia (PCP). Results From 2012 to 2018, 549 individuals with IFD and AID were included, mainly with PCP (n=227, 41.3%), fungemia (n=167, 30.4%) and invasive aspergillosis (n=84, 15.5%). Rheumatoid arthritis (RA) and anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) were the most frequent AID in PCP (n=55 and 25, respectively) and invasive aspergillosis (n=15 and 10, respectively), inflammatory bowel diseases (IBDs) were predominant in fungemia (n=36). At IFD diagnosis, 365 (66.5%) patients received glucocorticoids (GCs), 285 (51.9%) immunosuppressants, 42 (7.7%) tumor necrosis factor (TNF)-α blockers, 75 (13.7%) other biologics. Mortality at 30 days was 28.1% (143/508). Fungemia and high-dose GCs were independently associated with higher 30-day mortality. In PCP patients, lymphopenia <1500/mm3 was frequent (132/179, 73.7%) even if CD4+T cell count exceeded 200/mm3 in 56/78 patients (71.8%) (median 472.5/mm3, IQR 160–858). Conclusion IFD associated with AID occurs primarily in RA, AAV and IBD, especially when treated with GCs and immunosuppressants. Mortality is high, especially for patients on high-dose GCs. Lymphopenia may help identify risk of PCP, but normal CD4+T cell count does not rule out the risk. Further studies are needed to assess the individual risk factors for IFD.
Medecine et maladies infectieuses · 2017
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
RMD open · 2023 · Journal Article
Galmiche S, Thoreau B, Bretagne S, Alanio A, et al.
Medecine et maladies infectieuses · 2017 · Case Reports
Gaume M, Marie-Hardy L, Larousserie F, Lavielle M, et al.